Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 349

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 349
---
 pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our valuation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of September 30, 2025 and December 31, 2024.

16

Table of Contents

The following table summarizes our cash equivalents measured at fair value on a recurring basis as of December 31, 2024:Level 1Level 2Level 3TotalAssets:Cash equivalentsMoney market$35,865,754 $— $— $35,865,754 Total cash equivalents$35,865,754 $— $— $35,865,754 

Note 5 – Property and Equipment, net

Property and equipment, net consisted of the following:September 30,2025December 31,2024Computer equipment$589,094 $570,778 Furniture and fixtures98,628 98,628 Lab equipment1,236,233 1,236,233 Leasehold improvements298,941 298,941 Total2,222,896 2,204,580 Accumulated depreciation and amortization(1,330,343)(1,081,715)Property and equipment, net$892,553 $1,122,865 Depreciation and amortization expense totaled $78,841 and $88,949 for the three months ended September 30, 2025 and 2024, respectively. Depreciation and amortization expense totaled $248,628 and $269,691 for the nine months ended September 30, 2025 and 2024, respectively.

Note 6 – Accrued Expenses

Accrued expenses consisted of the following:September 30,2025December 31,2024Accrued professional services$1,033,244 $193,646 Accrued employee expenses2,822,836 3,583,649 Accrued research and development expenses3,518,288 1,106,872 Accrued other expenses108,774 88,962 Total$7,483,142 $4,973,129 

Note 7 - Common Stock

The Company had 200,000,000 authorized shares of Class A common stock, $0.001 par value per share as